Glucosamine for Osteoarthritis
Please read through the following information and click continue.
ACPE Universal Program Number:
207-000-09-008-H01-P
Release Date: August 1, 2009
Expiration Date: August 1, 2012
Statement
of Need
Osteoarthritis
(OA), also known as degenerative joint disease, is the most common type
of arthritis in the United States. Approximately 26.9 million adults 25
and older have OA, involving at least one joint, based on 2005
population estimates. In 2006, approximately 30 percent of adults 18
years and older reported experiencing some type of joint pain in the
previous 30 days, and $18 billion was spent on hospital costs
associated with total knee replacements.
Conventional treatments for OA may be unsatisfactory for patients. Dietary supplements, such as glucosamine, are widely promoted and available to the public as an alternative treatment for OA. Being medication experts and easily accessible to the public, pharmacists are likely to receive questions from patients concerning the safety and efficacy of glucosamine. Thus, the purpose of this article is to equip pharmacists with the tools to counsel patients on the use glucosamine for managing OA.
Learning
Objectives
Upon
successful completion of this activity, the pharmacist should be able
to:
- Describe the epidemiology, socioeconomic burden, and clinical features of osteoarthritis (OA).
- List conventional pharmacologic and supportive treatment modalities for OA.
- Explain the rationale behind using glucosamine as supportive treatment for OA.
- Discuss the safety and efficacy of glucosamine for OA based on evidence from recent controlled clinical trials.
- List key pharmacist-to-patient counseling points related to the use of glucosamine for OA.
Target
Audience
The
target audience for this activity is pharmacists.
Instructions
for Participation
To
receive a certificate of completion that indicates your eligibility for
continuing education credit, you must:
- Review the content of the activity.
- Successfully complete the post-test (70% or higher).
- You will have two (2) opportunities to successfully complete the activity.
Your statement of credit will be issued immediately upon successful completion of the post-test and submission of the evaluation.
Fee
There
is no fee for this activity.
Accreditation
Pharmacists
NCPA is accredited by the Accreditation Council
for Pharmacy Education as a provider of continuing pharmacy education.
This activity will provide 2.0 contact hours (.20 CEU) of continuing
pharmacy education credit under the number 207-000-09-008-H01-P.
Faculty
Darrell
Hulisz, RPh, PharmD,
is an associate professor of family medicineat the Case Western Reserve
University School of Medicine in
Cleveland, and is an associate clinical professor of pharmacy practice
at Ohio Northern University College of Pharmacy in Ada, Ohio.
Lauren Seibert, PharmD, is a pharmacist at Walgreens, Inc.
Disclosure
Declaration
It
is the policy of the National Community Pharmacists Association (NCPA)
to ensure independence, balance, objectivity, scientific rigor, and
integrity in all of their continuing education activities.
The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing educational ctivity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions) and drug delivery systems are subject to change, however, the reader is advised to check the manufacturer's package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Approval of credit for this continuing education activity does not imply endorsement by NCPA of any product or manufacturer identified.
Any medications or treatment methods suggested in this CE activity should not be used by the practitioner without evaluation of their patient's condition(s) and possible contraindication(s) or danger(s) of use of any specific medication.
Software
Requirements
| PC Windows 2000 SE or greater Internet Explorer 5.5 or greater Firefox *Adobe Acrobat Reader |
MAC |
*Required to view printable version of CE lesson |
|